Aconitic Acid

Aconitic Acid

SCHEMBL1289876

O=C(O)C=C(CC(=O)O)C(=O)O.O=C(O)C=C(CC(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 1.00
KDM4E B2RXH2 1/20 1.00
LDHA P00338 1/20 0.42
SRR Q9GZT4 1/20 0.42
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 1/20 0.41
CPB1 P15086 1/20 0.41
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.33
ABAT P80404 1/20 0.31
GABRR1 P24046 2/20 0.31
GABRR2 P28476 2/20 0.31
BLM P54132 2/20 0.31
GABRR3 A8MPY1 1/20 0.31
LMNA P02545 1/20 0.31
APEX1 P27695 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aconitic Acid SCHEMBL1275978 1.00 TSHR (1.00) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL16935 1.00 TSHR (1.00) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL219037 1.00 TSHR (1.00) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL2022211 1.00 TSHR (1.00) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL22334 1.00 TSHR (1.00) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL29245497 0.97 TSHR (0.95) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL9394649 0.97 TSHR (0.95) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL27871922 0.97 TSHR (0.95) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL30275008 0.97 TSHR (0.95) TSHRKDM4ELDHASRRALOX15
Aconitic Acid SCHEMBL27690462 0.97 TSHR (0.95) TSHRKDM4ELDHASRRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727448-A1 OPTICAL CHEMICAL SENSOR SYSTEM WITH MICRONEEDLES Cardiac Pacemakers, Inc. (US) 2026-04-22 EP disclosed
US-20260034177-A1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) 2026-02-05 US disclosed
EP-4578465-A1 INFECTION DETECTION SYSTEM Paul Hartmann Aktiengesellschaft (DE) 2025-07-02 EP disclosed
US-20240415417-A1 OPTICAL CHEMICAL SENSOR SYSTEM WITH MICRONEEDLES CARDIAC PACEMAKERS, INC. 2024-12-19 US disclosed
WO-2024258781-A1 OPTICAL CHEMICAL SENSOR SYSTEM WITH MICRONEEDLES CARDIAC PACEMAKERS, INC. (US) 2024-12-19 WO disclosed
US-20240415418-A1 OPTICAL CHEMICAL SENSOR SYSTEM WITH MICRONEEDLES CARDIAC PACEMAKERS, INC. 2024-12-19 US disclosed
CN-118804934-A Modified hyaluronic acid material and preparation method and application thereof 爱美客技术发展股份有限公司 2024-10-18 CN disclosed
CN-118613596-A Biomarkers for detecting and distinguishing invasive prostate cancer from inert forms and treatment of invasive prostate cancer 约翰霍普金斯大学 2024-09-06 CN disclosed
CN-118453562-A Nasal spray composition, nasal spray and application 森宝(杭州)品牌运营有限公司 2024-08-09 CN disclosed
US-12053552-B2 Functional wound dressing PAUL HARTMANN AG (DE) 2024-08-06 US disclosed
EP-3416658-B1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) 2023-03-22 EP disclosed
EP-3440999-B1 SYSTEMS INCLUDING ELECTROLYTE SENSOR FUSION CARDIAC PACEMAKERS INC (US) 2023-03-08 EP disclosed
US-11571151-B2 Implantable chemical sensor with staged activation CARDIAC PACEMAKERS, INC. (US) 2023-02-07 US disclosed
EP-3492014-B1 MULTIMODAL ANALYTE SENSORS FOR MEDICAL DEVICES CARDIAC PACEMAKERS INC (US) 2022-10-19 EP disclosed
US-11439304-B2 Systems and methods including electrolyte sensor fusion CARDIAC PACEMAKERS, INC. (US) 2022-09-13 US disclosed
EP-3495804-B1 IMPLANTABLE MULTIMODAL OPTOELECTRONIC ANALYTE SENSOR CARDIAC PACEMAKERS INC (US) 2022-05-11 EP disclosed
CN-114209684-A Application of itaconic acid in preparation of medicine for preventing and/or treating overweight or obesity or health-care product for preventing overweight or obesity 北京谷海天目生物医学科技有限公司 2022-03-22 CN disclosed
EP-2477962-A1 PRODRUGS OF GUANFACINE Shire LLC (US) 2012-07-25 EP disclosed
WO-2012046062-A1 USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS SHIRE, LLC (US) 2012-04-12 WO disclosed
WO-2011033296-A1 PRODRUGS OF GUANFACINE SHIRE LLC (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034177-A1 HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF EPCAM, CD44, SLC17A5 TSHR 2582/4885KDM4E 1778/4885LDHA 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.